What goes into the next treatment?

The MMRF Precision Medicine Model is injecting speed into drug development.
Dear Supporter,

The treatment of myeloma has seen some of the most significant advances of any cancer in the last decade. Despite these advances it is still a devastating disease. Now more than ever it is absolutely essential that we band together to fight this disease and identify new treatment options in our drive to a cure for patients.

2015 has been an important year in the fight against multiple myeloma. Numerous clinical trials are launching to study drugs for patients who had few or no treatment options available, and the myeloma community at large — researchers, industry, academia — is coming together like never before. Together with our partners we are accelerating breakthroughs for patients thanks to your efforts and support of the MMRF.

The MMRF has re-engineered the disease research and drug development model to integrate data and partnerships to inject speed and efficiency into the process with the ultimate goal of accelerating a cure. Through this model, seven new treatments have been launched for patients in the last 10 years. These treatments have almost tripled patients’ life span. You can learn more about our model in the article on page 4.

We are on track to launch 11 new clinical trials this year to rapidly advance lifesaving treatments to patients who are most in need. Thus far, we have launched three company-sponsored trials of completely novel, innovative drug programs: a Phase 2 clinical trial of selinexor with Karyopharm Therapeutics, Inc., a Phase 2 trial to test Janssen Biotech, Inc.’s daratumumab in smoldering multiple myeloma patients, and a Phase 1 study of Genentech’s immune checkpoint inhibitor, MPDL3280A. Read more about clinical trials we have launched on page 8. It is the support and funding of our donors and partners that will help us launch the remaining eight trials we have planned for 2015. Please take a moment to fill the envelope in our summer fundraising insert.

With your help, we are curing cancer now. On behalf of all of us at the MMRF, we thank you for your continued contributions that enable it to happen.

Sincerely,

Walter M. Capone
President and Chief Executive Officer, MMRF
Features

The MMRF Model

4 COVER STORY
The MMRF Precision Medicine Model is transforming the path to a cure.

6 ESTABLISHED AND EXPERIMENTAL TREATMENTS
The number of treatments is increasing.

14 INTRODUCING MyMMRF
A comprehensive new program empowers patients and caregivers.

Patient Empowerment

12 BEING A KNOWLEDGEABLE PATIENT

Drug Development

8 MMRC PIPELINE REPORT

10 MMRF COMMPASS STUDY™ PROGRESS REPORT

16 WE ARE CURING CANCER NOW

People

11 MMRF RESEARCH FELLOWS

17 TOM BROKAW ON DATELINE

18 MEET THREE MMRF CANCER FIGHTERS

20 IN-DEPTH INTERVIEW WITH JOAN LEVY, VICE PRESIDENT OF RESEARCH

Events

22 MMRF CHICAGO AWARDS DINNER

23 MMRF LAUGH FOR LIFE

24 INDEPENDENT EVENTS

25 MMRF TEAM FOR CURES

31 CALENDAR

MMRF in the News

29 MMRF MEDIA HIGHLIGHTS
The MMRF Precision Medicine Model

The MMRF actively drives drug discovery and development with a unique model that has proven results. It is comprised of three interrelated parts.

The Data Bank

An unprecedented collection of high-quality patient molecular and clinical data.

The Learning Network

Collaboration that focuses upon access to new targets and drugs to advance trials faster than any other organization.

The Clinic

A network of best-in-class partners launching clinical trials 60% faster than average.

The Data Bank
In 2005, the MMRF established the first comprehensive tissue banking effort in multiple myeloma. It has accessed over 4,000 patient samples and clinical data from newly diagnosed and relapsed patients.

The MMRF Tissue Bank fueled the Multiple Myeloma Genomics Initiative (MMGI) containing molecular profiles of 500 relapsed/refractory patients to obtain "blueprints" of particular forms of myeloma and help identify treatment options. In July 2011, the MMRF CoMMpass Study℠ began collecting clinical information and sequencing myeloma cells from patients' bone-marrow samples to generate genetic information from 1,000 newly diagnosed patients. The goal is to track molecular changes and how the disease progresses over at least 8 years for each patient. This will create the largest, most comprehensive catalog of multiple myeloma genomic and clinical data, and enable physicians to match specific treatment approaches to the patients most likely to benefit. We are also conducting side-by-side evaluations of new diagnostic technologies designed to detect minimal residual disease (MRD) in 400 newly diagnosed patients that
We saw an opportunity to speed up the development of new treatments, and built a model to achieve it.

Harlan Stone, Double Data Donor

Harlan Stone is a survivor of olfactory neuroblastoma, a very rare form of cancer with only about a thousand documented cases in the history of medicine. When Kathy Giusti urged him to have his tumor sequenced, it was a first for that type of cancer. Now there is a research project at Johns Hopkins. “I realized how powerful it could be,” he says. “The tools, the sequencing, what we know about genetics could help create opportunities to treat cancer more effectively, more rapidly.”

As a cancer survivor and MMRF supporter, Harlan appreciates how the MMRF is paving the way. Its use of clinical big data to accelerate cures for multiple myeloma also serves as a model for other cancers. “Personalized medicine and genetic understanding, I realized, were a big part of the future. I’m very excited to be part of that data share.”

Harlan is a data bank donor in another important way. He has made a sizable financial contribution to the MMRF Data Bank initiative. Some years ago, before he was diagnosed with his cancer, he received a mailing from the MMRF that said, “When two great organizations collaborate, innovation accelerates.” “I still keep that on my desk,” he says. “The concept of sharing information has motivated me to say this is where it’s going, this is where the help will come from. I have great respect for the MMRF and its commitment to do meaningful research that is not just following the current path.”

The Learning Network

The clinical and molecular data from the Genomics Initiative and the MMRF CoMMpass Study are housed in the MMRF Researcher Gateway, enabling researchers worldwide to access and utilize the data to form new hypotheses and study patient outcomes in novel ways. The MMRF CoMMunity Gateway is a unique informational and social forum aimed at fostering precision care by matching patients to the right trials and treatment opportunities. Our Collaborative Networks of Excellence bring together the brightest minds in myeloma to forge advances for research into new immune therapies and molecular-based treatments. And with partners such as GNS Healthcare, we now have the technology available to apply cutting-edge computer models of myeloma itself and analytics to uncover disease pathways, pushing us closer to a cure.

The Clinic

Together with 22 leading academic and community centers and a wide range of pharmaceutical, biotech and diagnostic partners, the Multiple Myeloma Research Consortium (MMRC) is aggressively investigating many molecularly targeted, immune, and novel agents. We are also working on a Master Protocol approach — a unique and modern pivotal trial design that could dramatically accelerate the development of targeted therapies by addressing many of the challenges of traditional clinical trials such as cost, patient participation and effective design. This unprecedented and unmatched clinical development platform is speeding, refining, and enhancing clinical trial enrollment, reducing the cost of drug development, and ultimately—by determining the best therapeutic fit for patients — improving treatment outcomes.
Established and experimental treatments

Drug classes, and the number of treatments within them, are on the increase.

Treatments can be classified based on similarities in behavior, similarities in chemical structure, and by the way they are used to treat a particular condition. Treatments are particularly effective when drugs from different classes are given simultaneously, in combinations of two or three.

Immunotherapies and Antibodies

Immunotherapy is the newest approach to multiple myeloma treatment. It is an umbrella term that describes different ways to stimulate the immune system and enhance its ability to attack cancer cells. Many of these treatments involve antibodies that target specific proteins found on multiple myeloma cells. These drugs are still in clinical trials but show considerable promise.

In Development

- Monoclonal Antibodies (e.g., anti-CD 38 inhibitors, checkpoint inhibitors, etc.)
- Vaccines
- Adoptive T-cell therapy

In Phase 3

- Daratumumab (monoclonal antibody)
- Elotuzumab (monoclonal antibody)

Researchers are finding ways to enable immune cells to attack cancer cells.
Novel Agents and Mechanisms refer to drugs that work in new ways currently being investigated in clinical trials. Often these drugs come from a new class, and they have the potential to provide new treatment options.

Novel Agents
Proteasome inhibitors and immunomodulatory drugs currently form the backbone of treatment for multiple myeloma. Proteasome inhibitors work by blocking the function of proteasomes, whose role is to break down proteins in both healthy and cancerous cells. Approved drugs in this class are administered via injection or intravenously. Ixazomib, a drug that is currently in a Phase 3 trial, is taken orally.

Approved Drugs
- Velcade® (bortezomib)
- Kyprolis® (carfilzomib)

In Phase 3
- Ixazomib (MLN9708)

Immunomodulatory, or IMiDs, work by stimulating natural killer cells and activating T-cells, reducing the growth of myeloma cells.

Approved Drugs
- Thalomid® (thalidomide)
- Revlimid® (lenalidomide)
- Pomalyst® (pomalidomide)

Novel Mechanisms
There are a number of emerging classes of drugs targeting specific defects within cells that are associated with the development and progression of multiple myeloma. These new agents are typically combined with proteasome inhibitors and/or IMiDs and could benefit a broad range of patients.

Approved Drug
- Farydak® (panobinostat) – histone deacetylase inhibitor

In Development
- Bromodomain Inhibitors
- Kinesin Spindle Protein Inhibitors
- SINE Inhibitors

Targeted Therapies
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules that are involved in its spread.

Sample Classes in Development
- BRAF Inhibitors
- FGFR3 Inhibitors
- Kinase Inhibitors (CDKs)
- MEK Inhibitors

Join us for a free Immunotherapy Webinar
Join us August 13, 2015 for the first in a series of webinars to learn more about the role of the immune system and activating it in the fight against multiple myeloma using the latest advances in immunotherapy.

Webinar 1: Antibodies: The Body’s Foot Soldiers in the Battle Against Disease
Check our website themmrf.org for more details and how you can register.

Moderator
Joseph Mikhael, M.D., Mayo Clinic, Arizona

Faculty
Don Benson, Jr., M.D., Ph.D.
The Ohio State University
Sagar Lonial, M.D., FACP, Winship Cancer Institute of Emory University

Supported by
Bristol-Myers Squibb
Multiple Myeloma Research Consortium (MMRC) pipeline offers promising treatments for patients

Clinical trials promise innovative therapeutics to help extend and save the lives of those living with multiple myeloma

A Record Breaking Year

In 2014, the MMRC, along with our industry and academic partners, opened a record number of clinical trials — a total of 10. These trials spanned the multiple myeloma spectrum — testing drugs in relapsed/refractory patients as well as recently diagnosed patients and those in the post-transplant setting.

In the first half of 2014, we opened six trials to study drugs that align with our core research priorities: immunotherapies and antibodies, and novel agents and mechanisms. Covered in the previous installment of Accelerator, these included:

- **Marizomib (NPI-0052)** in combination with Pomalyast® and low dose dexamethasone — Novel Agent
- **Imbruvica® (ibrutinib)** in combination with Kyprolis® — Novel Mechanism
- **Selinexor (KPT-330)** in combination with Kyprolis® and dexamethasone — Novel Mechanism
- **SAR650984 (anti-CD38)** — Antibody
- **Ixazomib (MLN9708)** in combination with Pomalidomide — Novel Agent
- **CB-5083** — Novel Mechanism

The second half of the year was equally successful, with the opening of an additional four trials. These included two Phase II trials evaluating ixazomib in the post-transplant setting. Ixazomib is an oral proteasome inhibitor currently in the final stages of clinical development, which will provide new insights on easier and more convenient ways to administer drugs of this class.

- **Ravi Vij, M.D.** at Washington University is leading a Phase II Study of ixazomib, Revlimid, and dexamethasone (IRD) for consolidation therapy post-Autologous Stem Cell Transplantation (ASCT) followed by maintenance with ixazomib or Revlimid.

- The second study, a Phase II randomized trial of continuation of post-transplant maintenance with single-agent Revlimid vs. consolidation/maintenance with ixazomib, Revlimid, dexamethasone in patients with residual myeloma, is being led by Andrzej Jakubowiak, M.D., Ph.D. at the University of Chicago.

Another trial that opened at the end of 2014 is studying a novel, four-drug combination of Velcade® (bortezomib), Revlimid, dexamethasone and elotuzumab in newly diagnosed multiple myeloma patients. Elotuzumab is an antibody that is currently in late stage clinical development and works by two distinct mechanisms. This antibody can bind to a protein (SLAMF7) on the surface of myeloma cells and signal the immune cells to destroy the tumor. Additionally, elotuzumab can directly activate the types of immune cells needed to destroy myeloma tumor cells.

The lead site for this clinical trial is Dana-Farber Cancer Institute and is being overseen by Paul Richardson, M.D. and Jacob Laubach, M.D., M.P.P.

Finally, a Phase Ib study of SAR650984 antibody is being tested in combination with Kyprolis® (carfilzomib) in relapsed/refractory patients. The lead MMRC investigator is Tom Martin, M.D. of the University of California, San Francisco. The MMRC is also studying this investigational treatment in combination with Revlimid and dexamethasone and as a single agent.
What’s Next

So far this year, the MMRC has announced three company-sponsored trials that are being offered at a number of sites.

A Phase II clinical trial is studying Karyopharm Therapeutics, Inc.’s selinexor, a novel agent, in combination with low-dose dexamethasone in highly refractory patients. The MMRF recognized the potential of selinexor in 2010, and awarded Karyopharm Therapeutics, Inc. a Biotech Investment Award to help advance the drug from preclinical analysis through the initiation of clinical testing in patients. In 2014 the MMRC launched a Phase I clinical trial to assess selinexor in combination with Kyprolis in relapsed/refractory patients. This trial is targeted for patients who are refractory to prior therapies of proteasome inhibitors and immunomodulatory drugs.

Also this year, the MMRC became involved in its first trial to evaluate the effects of an agent in patients with smoldering multiple myeloma. Janssen Biotech, Inc.’s daratumumab is an anti-CD38 antibody that is in late stage clinical development for myeloma. This drug has the potential to harness the body’s immune system to destroy myeloma tumor cells. Many MMRC sites will be involved. Ohio State University and Sara Canon Research Institute were some of the first MMRC sites to open and Sagar Lonial, M.D. at Emory University and Craig Hofmeister, M.D. at The Ohio State University worked closely with Janssen Biotech, Inc. on the study design for clinical study.

Last but not least, we opened the first trial within the MMRC focused on a class of drugs known as immune checkpoint therapies. Immune checkpoint therapies restore the T-cells’ ability to effectively detect and attack cancers cells. Immune checkpoints ultimately are used to block the immune response and therefore cancer cells use these checkpoint pathways to avoid being recognized and killed by the host’s immune system. Antibodies directed against these immune checkpoint proteins, like MPDL3280A, allow the immune cells to once again recognize and destroy the cancer cells. Immune checkpoint antibodies have been approved in other cancer indications. In this Phase I study, MPDL3280A from Genentech, an anti-PDL1 antibody, will be given in combination with Revlimid to relapsed patients and as a single agent to patients who have residual disease post-autologous stem cell transplant.

MMRF and MMRC support a robust clinical pipeline

<table>
<thead>
<tr>
<th>Immunotherapies and Antibodies</th>
<th>Targeted Therapies</th>
<th>Novel Agents</th>
<th>Novel Mechanisms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daratumumab</td>
<td>AT7519</td>
<td>Ixazomib</td>
<td>ABT-199</td>
</tr>
<tr>
<td>Elotuzumab</td>
<td>GSK21110183</td>
<td>Marizomib</td>
<td>ARRY-520</td>
</tr>
<tr>
<td>MPDL3280A (PDL-1)</td>
<td>OSI906</td>
<td></td>
<td>CB-5083</td>
</tr>
<tr>
<td>SAR650984</td>
<td>PD0332991</td>
<td></td>
<td>Ibrutinib</td>
</tr>
<tr>
<td>Siltuximab</td>
<td></td>
<td></td>
<td>Selinexor</td>
</tr>
</tbody>
</table>

New Diagnostic Approaches

- Janssen Diagnostics, LLC, CELLSEARCH® Circulating Tumor Cell (CTC) Test
- Sequenta LymphoSIGHT™

If you have any questions about the clinical trials that have been initiated over the last 18 months, or believe you may be eligible, please call our nurse hotline at 1-866-603-6628.
The MMRF CoMMpass Study℠ is the organization’s landmark research study in patients with newly diagnosed active multiple myeloma, and the cornerstone of the MMRF’s precision medicine initiative. The goal is to map the genomic profile of up to 1,000 myeloma patients at diagnosis, and at multiple points throughout the course of the disease, helping researchers to understand how each patient responds to different treatments over time.

By obtaining an unprecedented level of clinical and genomic information — from initial diagnosis for at least eight years — and then linking this data to patients’ responses to treatment, the study will accelerate new and effective therapies for patients, and provide unique information that may also lead to the beginning of cures for various subtypes.

It is critical to provide researchers and clinicians with uninhibited access to data. The MMRF breaks down traditional barriers that have slowed research in the past by sharing data with industry and academic partners and encouraging them to work together to accelerate research and cures. We believe the MMRF CoMMpass Study will revolutionize the way multiple myeloma is treated.

**Recent Progress**
The fifth data release — or interim analysis as you may see it referred to — occurred in March 2015. This release made the genomic data from 190 participants available on the MMRF Researcher Gateway.
The data also included the first comparisons of molecular changes that occurred at diagnosis and at points of progression from the same patient. This means that researchers will be able to better understand how myeloma changes over time in a specific patient, allowing healthcare professionals to adjust the course of treatment based on a patient’s unique genetic profile.

**About the MMRF Researcher Gateway**
The MMRF Researcher Gateway is an information ecosystem designed to make key genomic and clinical data from the CoMMpass Study accessible to scientists as they test various hypotheses with the intention of driving discoveries in multiple myeloma.

Approximately every six months, we provide researchers and healthcare professionals with updated data through our Researcher Gateway.

By participating in the MMRF CoMMpass Study, patients are helping to accelerate the next generation of multiple myeloma treatments. Our next data release will be available later this summer.

To learn more about the MMRF CoMMpass Study visit themmrf.org/CoMMpass.
The MMRF hosted a symposium and reception to congratulate our Research Fellow Award winners from the last few years. Eleven MMRF Research Fellows from across the globe presented the research they’ve undertaken to advance treatment in multiple myeloma. Joan Levy, Vice President of Research of the MMRF and MMRC, welcomed the Fellows and their mentors, highlighting the diversity of preclinical and clinical research that was presented — from new models to identifying novel targets and inhibitors — all driving the field of myeloma research forward toward a cure. This award program was the first of its kind for MMRF Research Fellows, and it provided a forum for Fellows to interact and hopefully collaborate on future endeavors. We look forward to hosting future events!

John Carpten, Ph.D., Deputy Director of Basic Sciences at the Translational Genomics Research Institute (TGEN) is a mentor to MMRF Research Fellow Award winner Bodour Salhia, also of TGEN. He praised the Fellows program as critical to providing “support and encouragement for young scientists,” and noted, “It is important for those who support the MMRF to know that they are helping to develop the next generation of young bright scientists into the field of multiple myeloma.”

Fellows who were recognized at the reception include:

- **Ernesta Paola Neri**, University of Calgary
- **Yuhuan Zheng**, MD Anderson Cancer Center
- **Jianjun Zhao**, Dana-Farber Cancer Institute
- **Bodour Salhia**, Translational Genomics Research Institute
- **Kate Vandyke**, Institute of Medical and Veterinary Science, Adelaide, AU
- **Bruno Paiva**, Hospital Universitario de Salamanca, Spain
- **Jana Jakubikova**, Dana-Farber Cancer Institute
- **Xingding Zhang**, MD Anderson Cancer Center
- **Leslie Crews Robertson**, University of California at San Diego
- **John Simmons**, National Cancer Institute
- **Eric Smith**, Memorial Sloan-Kettering Cancer Center

A special thank-you to our corporate sponsors, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Novartis, Onyx, Pfizer, and Takeda Oncology for making this reception and research possible!

From left: Xingding Zhang, Ernesta Paola Neri, Leslie Crews Robertson, John Simmons, Jana Jakubikova, Mary DeRome, Joan Levy, Mohit Verma, Bodour Salhia, Jianjun Zhao, Kate Vandyke
Being a knowledgeable patient
Creating your treatment roadmap

Being an Empowered Patient
Regardless of the type, stage or prognosis, cancer is a life-altering event. Each person’s experience with cancer is a unique journey.

In today’s world, patients are not only at the center of their own care, but the single most important drivers of their cancer experiences. There is a powerful revolution under way—that of the informed cancer patients who bank their tissue for future study; who question whether they harbor genetic mutations and other abnormalities for which lifesaving new treatments already exist or are under study in clinical trials; and who share their data to accelerate research breakthroughs. At the MMRF, we encourage you to be an empowered patient.

MMRF Founder and Executive Chairman Kathy Giusti recently published an article in the Huffington Post entitled “Becoming Your Best Cancer Care Advocate: 5 Steps Could Make All the Difference.” By following her five steps, Kathy believes that cancer patients can take control of their care and ensure that they receive the individualized attention they deserve. The steps are:

1. **Know your disease inside and out**
2. **Integrate your team**
3. **Bank your samples**
4. **Know your sequence**
5. **Look beyond your treatment center**

Knowledge is Power
Would you purchase a car without test driving it? Start a new job without knowing the job description? Buy a new house sight unseen? No. Knowledge is power; power to make informed decisions.

As soon as you are diagnosed, work to learn as much as possible about your specific disease, its treatments and the potential effects on your body both short and long-term; research treatment guidelines, typical protocols and investigational treatments that may be available to you.

Write down all of your questions and demand answers.

Knowledge is Power
PATIENT EMPOWERMENT

**Power in Numbers**

Throughout your cancer journey you will most likely encounter a variety of specialists, as well as solicited and unsolicited opinions from everyone around you. Nominate an advocate to help you manage your healthcare team.

Regardless of who your caregiver is, this advocate needs to be just as informed as you are, a true partner who will help navigate your journey.

With the help of your advocate, begin selecting the rest of your healthcare team. Find a doctor who specializes in treating your specific type of cancer. Be sure to research and discuss:

- Their credentials
- The research studies they have/are participating in
- Their adherence to state medical boards
- Their education
- Their hospital affiliations
- Their accessibility (will they be there for you if you have a question in the middle of the night or on weekends?)
- Who will coordinate your care — surgeon, medical oncologist, radiologist, etc.

Ask for at least two referrals. Speaking with patients who have had a personal experience with the doctor you are considering is one of the best ways to supplement your internet research and ensure you are 100 percent comfortable with your decision.

As you form your healthcare team also be sure to consult with social workers to understand the financials associated with your care and seek psychological counseling. Most importantly, seek a second opinion and look beyond your cancer center, if necessary.

Ensure that your healthcare team is connected with one another and that each specialist receives updates on your treatment and developments. Consider setting up a group email address to easily share important information with your entire team at once — and encourage them to communicate with one another.

**Establishing Your Roadmap**

Once you’ve conducted your own research, selected your healthcare team, and have your questions in hand, work with your primary doctor to learn your prognosis, your numbers, your treatment plan and what you can expect from treatment. Then consult with your full team to arrive at a consensus.

The most powerful roadmap will be one that is constantly adjusted to ensure you get the individualized help you need on an ongoing basis. Never stop researching and asking questions:

- Should I change my treatment course or make a transition off active treatment?
- Should I take into consideration quality of life?
- Should I consider genetic testing?
- Should I bank my tissue?
- What will my needs be post treatment?

Each time your doctor takes a tissue sample to biopsy or analyze, ask your doctor to save the sample. This first tissue sample may hold valuable clues about your disease and could be important to doctors later, because it has not yet been altered by treatment. In addition, request to have your genome sequenced. This is not common practice for all cancer diagnoses, and it will be important that you vocalize this to your treatment team.

Finally, over the course of treatment, you may consider alternative options for care — such as a new clinical trial. Your healthcare team should be open to and knowledgeable about all of your available choices, and should act as your ally in making sure you get the best care possible.

At the MMRF, we’ve built a community of patients and the infrastructure to share and exchange knowledge, but this will only get us so far. Patients, too, must take charge of their cancer care, from the moment of their diagnosis and throughout their patient journey.

Knowledge is power and you’re not in this alone.
Introducing MyMMRF
A comprehensive program that puts opportunities and resources online—and empowerment at your fingertips

The more you learn about multiple myeloma, the efforts that are being made to cure it, and the resulting treatments that are available, the better your decisions will be. To be empowered as a patient or a caregiver, you need reliable, trustworthy, and up-to-date information. That is why we created an online resource called MyMMRF.

MyMMRF gives you access to the resources we are continually building as the leading multiple myeloma research organization. We know how important finding the right multiple myeloma cancer treatment center is. We strongly advocate banking your tissue samples for future study and having your genome sequenced to see if treatments exist or are being tested for your genetic mutations. We know that becoming involved in clinical trials can provide early access to potentially successful treatments. You will be able to do all this and more through MyMMRF. Here is a preview of the resources you can find there.

My partner in finding the right cancer center for me
Steps taken after diagnosis can have an impact on the quality of care you receive. Finding the right doctor is important because treatments for multiple myeloma are emerging at an exciting pace. You can find multiple myeloma specialists who are affiliated with leading cancer centers on our website.

My opportunity to hear leading clinicians and researchers
Our day-long Patient Summit events, which are offered at no charge, provide the latest information about the disease, current treatment options, clinical trials, and recommendations for optimal disease management. Speakers include renowned clinicians and researchers, and patients who share their experiences in navigating the disease. You can also watch videos from the Patient Summits online anytime at MyMMRF.
My connection to other patients and caregivers like me
Finding a cure depends on everyone in the multiple myeloma community — researchers, industry clinicians and patients. That is why the MMRF established the MMRF CoMMunity Gateway, where patients and caregivers can go online and share their journey as active participants in our search for better, more targeted treatments. Our future hope is that these same patients, as they eventually have their genomes sequenced and learn which, if any, mutations they have, can connect with other patients like them, engage with researchers who specialize in that particular area of genomics, and sign up for clinical trials that might be right for them.

My trusted guide to clinical trials that may help me
Take action! Participating in clinical trials is an important treatment option because you may get access to potentially life-extending drugs that are not yet widely available, and help medical research bring us closer to a cure. Using our online trial finder can guide you to trials that even your doctor may not know about.

My provider of practical and helpful resources
In addition to ready-to-print educational materials, MyMMRF provides access to organizations that offer financial help for treatment, and other kinds of support.

My oncology nurse
To talk to a nurse, call 1-866-603-6628 with any questions you may have. You can also consult our online FAQs.

My choices
Those who have the disease are the biggest stakeholders in the quest to cure multiple myeloma. MyMMRF is one of the ways we are helping to empower patients, with help from caregivers, to be their own advocates. Visit themmrf.org/mymmrftoday.
We are curing cancer now

We have industry-leading momentum, but there is still more work to be done.

We need your support.

The MMRF and its partners have fueled more studies, completed more trials, introduced more medicines, and had a far greater effect on patients than any other organization. We have brought seven drugs to market since 2003 and tripled the expected life span. Today we are advancing breakthrough treatments within each of the most promising new drug categories. The pipeline of new treatments has the potential to dramatically increase patient life span and has never been more robust. The MMRF Campaign will enable us to triple our speed. We have the model. We need your help in funding it.

Our Data Bank holds answers
Precious information that we are learning to decode is contained in the MMRF Data Bank, an ambitious gathering and analysis of genetic and clinical patient data.

Our Learning Network inspires new approaches
Collaboration rather than competition speeds discovery. By sharing our data and the resulting discoveries, the MMRF Learning Network provides researchers with fertile ground to form promising hypotheses for testing.

Our clinical research group brings potential treatments to patients
The Multiple Myeloma Research Consortium (MMRC) is our clinical research arm. This network of best-in-class partners is instrumental in launching clinical trials and getting treatments to patients faster. We open trials 60% faster than the industry average.

Funding is needed more than ever in this transformative time.
There is more promise than ever before. In the next three years, we will accomplish as much to help patients as we have in the past decade. Multiple myeloma patients don’t have time to waste, so please contribute now.

We have 11 new potentially life-extending treatments that patients are waiting for, but we cannot open the trials without your support.

Please give today at themmrf.org/donate

We are curing cancer

We have the power to leverage all of our progress, partnerships, and models into new treatments and cures for patients.
Tom Brokaw puts multiple myeloma in the national spotlight on Dateline.

Multiple myeloma is ready for prime time

NBC News Special Correspondent and bestselling author of The Greatest Generation, Tom Brokaw has led a fortunate life with a strong marriage and family, many friends, and a brilliant journalism career. But in 2013, back pain led him to doctors at the Mayo Clinic, and his run of good luck was interrupted. He had multiple myeloma.

Approaching his treatment with the curiosity and tenacity of a journalist, Brokaw began to keep a journal. He was determined to learn as much as he could about his condition, to report the story, and help others facing similar battles. That journal became the basis for his latest book, A Lucky Life Interrupted: A Memoir of Hope.

On May 7, 2015, Tom Brokaw appeared on NBC’s Dateline to share the story of his personal battle with multiple myeloma. With a mass audience, the episode greatly raised awareness of multiple myeloma, and spotlighted the role of the MMRF in aggressively working to find a cure. He acknowledged the game-changing model developed by the organization. “MMRF became a foundation with a corporate attitude about making change happen quickly through innovation.”

Kathy Giusti, MMRF Founder and Executive Chairman, was featured as well. Both Kathy and Tom spoke about the importance of patients and families taking an active role in managing their disease. The MMRF is grateful to Tom Brokaw and NBC for sharing important information and hope with myeloma patients and the wider community of people affected by cancer.

A Lucky Life Interrupted: A Memoir of Hope

Tom Brokaw’s journal of his battle with multiple myeloma is the basis of this memoir, the story of a man coming to terms with his mortality, contemplating what means the most to him now, and reflecting on what has meant the most to him throughout his life. Brokaw also writes about the importance of patients taking an active role in their own treatment, and of the vital role of caretakers and coordinated care.

To learn more about the book visit themmrf.org/tom-brokaw or receive it as our gift with a contribution of $250 or more to the MMRF at themmrf.org/donate.
Leadership News

Meet three MMRF cancer fighters

Jennifer Toups, Clinical Research Associate for the MMRF CoMMpass Program

Jennifer Toups, who holds a Master of Science degree in cellular biology and anatomy, is a Clinical Research Associate for the MMRF CoMMpass Study. Previously, she was an Associate Director of Clinical Trials and Regulatory Affairs at the University of Arkansas Myeloma Institute for Research and Therapy (UAMS). In addition to her professional connection to myeloma, she also has a personal one. Her dad had it.

At the MMRF, Jennifer plays an important role in helping to run the MMRF CoMMpass Study. She is the liaison among the participating sites in the Multiple Myeloma Research Consortium (MMRC), keeping on top of data entry and making sure the patients are being followed according to study protocol. She works with coordinators and investigators at the sites that see patients and keeps doctors informed when a patient’s disease progresses and a second or third bone marrow sample is needed, because tracking genetic changes over time is critical.

“Working with this disease means so much more to me than just a job,” she says. “It’s a passion.” That shared commitment is something Jennifer appreciates about the MMRF. "Before, I might have been helping people be treated. Here I’m helping people be cured. I have a picture of my father up in my cubicle and I look at him every day and remember why I am here.”

Laura Gilman, Vice President of Events

Before joining the MMRF in 2010, Vice President of Events Laura Gilman had over 15 years of experience designing and executing revenue-generating events and initiatives for Citigroup, Victoria’s Secret, and Morgan Stanley. Today, she is overseeing the team planning events, from the hyper-local MMRF 5K Run/Walks to the annual Fall Gala.

“The events are very moving, very emotional,” she says. “People know they’re raising money for a cure.” Seeing patients, their families, and their friends become empowered by making a difference is “life changing.”

Laura says that even people not affected by — or aware of — multiple myeloma become advocates for the MMRF. “They come in because they want to do an Ironman® and they leave being an MMRF ambassador. We are getting converts because they’re inspired by our story and feel that the MMRF model is going to change the medical research landscape. We’re getting our message out. It’s not just about multiple myeloma.”
One of the highlights of Paul Bassett’s career in pharmaceutical drug development is an award he received for creating a new dosing protocol for Phase 1 clinical research sites, which resulted in an annual savings of $325 million. He was also awarded funding to develop a smartphone app currently being used to determine patient eligibility in real time. Clearly, Paul is well qualified to be the “boots on the ground” in his role as Clinical Trials Manager for the Multiple Myeloma Research Consortium (MMRC). Paul helps to facilitate concept development and proposal submission, manage budgets and regulatory aspects, and drive to the startup phase — fast.

“We focus on accelerating the startup of clinical trials and getting them done faster than anyone else,” he says. “We’re pretty aggressive about clinical trials. One trial opened 111 days faster than non-MMRC sites and closed [enrollment] before 70% of non-MMRC sites could even get opened. It’s just tremendous in terms of bringing these medicines to patients who are out there waiting for them. There’s no greater sense of urgency than knowing that there are patients out there with an unmet need, or that these clinical trials could actually help them extend their lives or improve their quality of life. There are not enough hours in the day.”

SAVE THE DATE
SATURDAY, OCTOBER 24, 2015
MMRF ANNUAL FALL GALA
TO BENEFIT THE MULTIPLE MYELOMA RESEARCH FOUNDATION
HYATT REGENCY GREENWICH
OLD GREENWICH, CT
www.themmmrf.org/FallGala
An in-depth interview with Joan Levy
Fueling the pipeline of drug development

We sat down with Joan Levy, Vice President of Research at the Multiple Myeloma Research Foundation (MMRF) and its clinical research arm, the Multiple Myeloma Research Consortium (MMRC), to discuss her role and the revolutionary research the Foundation is involved with to advance the discovery and speed the development of multiple myeloma treatments.

Levy joined the MMRF eight years ago to focus more directly on patients. She came with extensive academic and industry experience, working in both oncology and osteoporosis. While she enjoyed being able to dig deep into the science during her time in academia and then get closer to treatments during her time in pharma, at the MMRF she hit the trifecta. Here, Levy is able to work with the best of the best in industry, academia and government, all while focusing on speeding the delivery of new treatments to patients.

Today, Levy helps bridge the gap between translational research and clinical development. She and the Research team are building a robust multiple myeloma clinical trial pipeline by working closely with industry to identify novel drugs and combinations that may be a match for a company-sponsored trial. Levy also works with investigators from the 22 sites of the Multiple Myeloma Research Consortium to launch investigator-sponsored initiatives.

Ultimately, Levy’s goal is to build a balanced pipeline of molecularly targeted, immune, and novel agents that will improve and extend the lives of myeloma patients. She does this by working with the clinical operations team to ensure that the transition from clinical trial concept to opening of the trial at MMRC sites happens as quickly and efficiently as possible. Last year, the MMRF opened a record number of multiple myeloma clinical trials, and Levy hopes to do so again this year.
Since I became involved with the MMRF grant program eight years ago, I have seen the number of junior investigators pursuing myeloma research grow each year. In fact, the number of MMRF Research Fellows doubled in 2014 compared to 2007, the year I started working at the MMRF! We are also seeing an increased number of multiple myeloma abstracts at major medical conferences, such as American Association for Cancer Research (AACR) Annual Meeting and American Society of Clinical Oncology (ASCO) Annual Meeting.

It is incredible to see the enthusiasm for research and collaboration grow as more and more researchers join the community.

The MMRF is known for collaborating with industry and academia partners, and has prioritized data sharing since its early days. Levy wants the research community to continue to share data in this way to help further myeloma research. According to Levy, if we are working together, the future of myeloma research looks bright.

What exciting research and clinical trials is the MMRC involved in?
The MMRC has built one of the most exciting, robust, and balanced clinical trial portfolios for myeloma patients. We are using our genomic findings to facilitate trials with drugs that specifically target identified genomic markers. For example, we are using the information we discovered through the Multiple Myeloma Genomics Initiative (MMGI) about the BRAF mutation in multiple myeloma to initiate a trial with a BRAF inhibitor in combination with another drug.

We are also opening trials that will bring new and promising immune oncology agents to multiple myeloma patients who may benefit from them.

What area(s) do you believe have the most potential?
The direction I’m seeing the field go — and I’m excited to see it go in — is treating the disease earlier. I believe there is undeniable potential there.

For example, patients with smoldering myeloma used to be monitored, but were never treated. Now there are clinical trials to determine whether we can cure smoldering myeloma, or at least delay progression of the disease, with early intervention.

How has myeloma research evolved over the past decade?
In addition to the therapeutic and research breakthroughs I’ve already highlighted, the biggest change is the number of investigators who are interested in myeloma research. Since I became involved with the MMRF grant program eight years ago, I have seen the number of junior investigators pursuing myeloma research grow each year. In fact, the number of MMRF Research Fellows doubled in 2014 compared to 2007, the year I started working at the MMRF!

The MMRF is known for collaborating with industry and academia partners, and has prioritized data sharing since its early days. Levy wants the research community to continue to share data in this way to help further myeloma research. According to Levy, if we are working together, the future of myeloma research looks bright.
On May 26, 2015, over 400 Chicago area patients, patient families, clinicians, researchers, businesses and supporters attended the 14th Annual Multiple Myeloma Research Foundation (MMRF) Chicago Awards Dinner and raised over $1,000,000 to fuel transformative cancer research and accelerate a cure NOW.

“We are extremely grateful to our generous Chicago supporters, many of whom have been with the MMRF since the event’s inception,” said Walter M. Capone, Chief Executive Officer and President of the MMRF. “Adding to their steadfast and continuous patronage is a vibrant force of new and young professional constituents whom we are most fortunate to have joining us in our mission. This level of funding allows us to rapidly advance cutting-edge research and accelerate the most promising, innovative and effective new therapies for patients in partnership with leading researchers and clinicians in institutions and companies worldwide.”

The MMRF was proud to honor actress, director, producer, writer and MMRF Honorary Board Member Bonnie Hunt with the Spirit of Hope Award. This award is presented annually to a patient, caregiver or individual who exemplifies the true spirit of hope – one who generously advocates for the benefit of others, works tirelessly to help cancer patients, and inspires hope through their perseverance. Academy Award-winning actress Marlee Matlin, whose father was a multiple myeloma patient, gave the evening’s keynote address. Also joining the evening’s honorees were actor, producer and writer Don Lake as the evening’s Master of Ceremonies and Jill Pflaum as the evening’s Patient Speaker.

Dixie-Lee Essletine, M.D., FRCPC, Vice President, Oncology Clinical research, Takeda, added, “We are honored to partner with the MMRF to support patients and their families on this special evening, as the presenting industry sponsor. At Takeda Oncology, we strive to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.”

1. Walter M. Capone, Karen Andrews, Marlee Matlin, Bonnie Hunt, Jill Pflaum, Dixie-Lee Esseltine, M.D., Don Lake
2. Marlee Matlin
3. The Zook Family, Walter M. Capone, Bonnie Hunt, Marlee Matlin
5. Bonnie Hunt
6. Dave Purcell
7. Dr. Andrzej Jakubowiak, Walter M. Capone
8. Don Lake
On May 5, 2015, nearly 700 tristate area patients, patient families, friends, doctors, businesses and supporters attended the 13th Annual Multiple Myeloma Research Foundation (MMRF) Laugh for Life: New York and raised $800,000 to benefit transformative cancer research and advance our mission to find a cure NOW.

“The MMRF Laugh for Life event provides us the opportunity to celebrate life through laughter and honor all who are united in our mission to cure myeloma and all cancers,” said Walter M. Capone, Chief Executive Officer and President of the MMRF. “Thanks to all who inspire and support events like ‘Laugh,’ we are able to accelerate the most promising, innovative and effective new therapies for patients, and advance cutting-edge research through our partnerships with the best scientists, researchers and clinicians in institutions and companies worldwide.”

The MMRF was proud to honor Stephanie Stoss, Senior Director of the Mount Sinai Medical Center – Cancer Network Bone Marrow Transplant, Multiple Myeloma, with the Carol Goldschein Spirit of Hope Award presented by Celgene Corporation. This award is presented annually to a patient, caregiver or individual who exemplifies the true spirit of hope – one who generously advocates for the benefit of others, works tirelessly to help cancer patients, and inspires hope through their perseverance. The MMRF was also proud to honor Sue Korn and Cindi Stern, founders of Laugh for Life: New York, with the MMRF Courage and Commitment Award. Joy Behar, Comedian, Writer, Actress and Emmy Award-Winning Talk Show Co-Host, served as headline performer for the night. Amy Freeze, television meteorologist with WABC-TV, served as the evening’s Mistress of Ceremonies.

“The MMRF is known for bringing great researchers, scientists and the multiple myeloma community together for a common cause, developing a plan to achieve that cause, and staying with it until the goal is achieved,” said Joel Beetsch, Vice President of Global Patient Advocacy at Celgene Corporation. “Celgene is proud to partner with the MMRF on behalf of the many, many patients and families it serves.”

1. Sherri Lippman and Sue Korn, Event Co-Chairs
2. Stephanie Stoss, Cindi Stern, Sherri Lippman, Joy Behar, Sue Korn, Michael Reinert, Anne Quinn Young, Amy Freeze
3. Joy Behar
4. Lori Saward
5. Chad Saward, Stephanie Stoss, Anne Quinn Young
6. Amy Freeze
Independent events

There are over 80 events that take place around the country hosted by amazing individuals like Ryan and Jana, who are both patients. These events raised close to $1 million for our critical research.

Cancer Blows

When world-class trumpeter Ryan Anthony was preparing for a stem cell transplant to treat his newly diagnosed multiple myeloma, his friend Doc Severinsen called to ask if there was anything he could do. “When I get through this,” Ryan said, “I want to stand on stage with you one more time.”

That was the inspiration for what became a once-in-a-lifetime musical event called Cancer Blows, which took place on March 4, 2015, thanks to the efforts of Ryan and his wife Niki. It featured Doc Severinsen, Lee Loughnane from the band Chicago, Arturo Sandoval, former trumpet players from Canadian Brass and other musical friends. Their goal was to raise both awareness and money for cancer research, with a focus on blood cancers and multiple myeloma.

And they succeeded to the tune of over $800,000!

When Ryan was diagnosed with multiple myeloma, he was considered high risk and unlikely to respond to treatment. Today, he is in remission. He is being treated with a medication that was funded and championed by the MMRF.

While Ryan knows that one day he will need a new treatment, he is encouraged by the progress the MMRF is making: “Look at all the options that the MMRF is bringing to the table. I know we can do this. But I also know it’s not going to happen without financial support.”

Memphis Miles for Myeloma

When Jana Stressel, who has multiple myeloma, and her husband Jay started their Memphis Miles for Myeloma 4 Mile Run/1 Mile Walk five years ago, they never dreamed it would be so much more than a way to support the MMRF. Today it is a very special gathering and support system for all those touched by multiple myeloma, and has raised nearly $100,000. “People come from all over now,” says Jana. “If you’re in Memphis November 14, 2015, you won’t want to miss it!”

And Jana Stressel
Spartan Obstacle Races

Citi Field (5/9) and Fenway Park (11/7)
125 MMRF Team for Cures athletes took on the Citi Field Spartan obstacle race on May 9, raising more than $125,000 for myeloma research. Corporate teams, groups of families and friends, and patients ran the 3-mile, 20+ obstacle course in this event, as the MMRF became the first charity to ever partner with a Spartan race in a stadium. The spirited competition awarded perpetual “cup” trophies to the biggest team, fastest team and the one that raised the most funds. The fastest man and woman as well as the biggest individual fundraiser were also honored with trophies. The MMRF is ready to do it all again at Boston’s beloved Fenway Park on Saturday, November 7. To learn more and sign up, visit themmrf.org/Spartan.

World Marathon Majors

The MMRF is the only U.S. charity to field teams for all of the “World Marathon Major” events. This series of elite 26.2 mile races includes New York City, Chicago, Boston, London, Berlin, and the recently added Tokyo Marathon. Avid runners put these impossible-to-get-into races on their bucket list. The MMRF can get you in! See themmrf.org/marathon.

TCS New York City Marathon

Join the MMRF Team for Cures at the New York City Marathon, perhaps the world’s most exciting and popular marathon. Gain priority access to our limited entries as well as a VIP experience including a team Coach Bus to the start, a MMRF tent at the staging area, a technical team jersey and more. Family, friends and MMRF supporters enjoy a catered lunch at the MMRF Cheer Zone supported by Takeda Oncology. Put more meaning into your training and running by joining the biggest MMRF marathon team and help cure cancer NOW! themmrf.org/2015NYC

Gain access to some of the most exclusive race events in the world, while helping to speed the cure of cancer. themmrf.org/EnduranceEvents
Team for Cures 5K Walk/Run

In 2014, 10,000 members of the myeloma community shared camaraderie, knowledge, and hope — and raised more than $2.1 million. So far in 2015, over 3,500 participants have raised over $1 million. We are also excited to announce the addition of new races in Atlanta and New York as well as a kids’ race and a tribute wall.

Philadelphia, 2014

**Honorary Race Chair:**
Dr. Edward Stadtmauer,
University of Pennsylvania

**Attendees:** ......................................... 1,244
**Funds Raised:** ............................... $256,996
**Top Team:** Kiss Myeloma ..........$62,835
**Top Individual:**
Lindsay Rohrbaugh ......................... $880

**Spirit of Hope Honoree:**
Joann Gilbert

At the 2013 MMRF DC 5K Walk/Run, Joann was determined to run the entire race. Her daughter-in-law, Shavalyea, kept her eye on Joann to make sure she was going to make it. When they were almost at the finish, Joann told her that she could not run another step. Shavalyea took Joann’s hand and told her, “You cannot give up, you can do it, you can do it!” ... and they crossed the finish line together! You’ve heard of the old proverb, “It takes a village to raise a child.” Joann’s village was TEAM GILBERT, comprised of family and friends that hung in there with Joann to get her where she is today.

Washington, D.C., 2014

**Honorary Race Chair:**
Dr. Dipti Patel-Donnelly,
Virginia Cancer Specialist

**Attendees:** ......................................... 1,216
**Funds Raised:** ............................... $236,231
**Top Team:** Team CHESS ..........$35,579
**Top Individual:**
Deidre Brown ...................................... $205

**Spirit of Hope Honoree:**
Paul Piazza

This courageous man lived to serve his family, community, and country. An Air Force Veteran of the Vietnam War as well as an Ex-Chief of the Patterson Fire Department, Paul was truly passionate about being there for others. In Paul’s honor, the team “Sunshine on my Shoulders” was created in both Chicago and Philadelphia.
San Francisco

Honorary Race Co-chairs:
Dr. Tom Martin and Dr. Jeffrey Wolf,
University of California, San Francisco

Attendees: ............................................. 808
Funds Raised: ........................................ $235,721
Top Team: Team Susie .................. $33,389
Top Individual: Jack Aiello .......... $52,000

Spirit of Hope Honoree:
Yvonne Cooper

In addition to Yvonne’s journey battling myeloma, she turns to outside resources for further help. She has been participating in the MMRF San Francisco 5K Walk/Run since 2003 because she is “convinced that there will eventually be a cure.” Her support group, San Francisco Bay Area support

Boston

Honorary Race Chair:
Dr. Paul Richardson,
Dana-Farber Cancer Institute

Attendees: ............................................. 2,047
Funds Raised: ........................................ $388,097
Top Team: Team Multiple Miracles ....... $21,545
Top Individual: Paul Carter .................... $20,230

Spirit of Hope Honoree:
David Boudreau

David has his picture hanging in Hudner Oncology Clinic at St. Anne’s Hospital in Fall River, Massachusetts because he is a multiple myeloma survivor. Like many, his story of battling cancer has not been easy. This disease has brought him many struggles and setbacks. In spite of this he

stands strong, has never given up, and continues to fight. He is not only seen as a cancer survivor, but more importantly a face of hope for so many.
Alex Burke has been an inspirational young leader in this fight against multiple myeloma. In 2008, Team Darien was formed which included Alex’s family, friends and their Darien community. Over the past three years, Team Darien T-shirts had the slogan “Walk, Jog, Run, Sprint, Cure.” With this slogan, they encourage everyone to attend and participate in the race whether they are competing or walking. When Alex was 11, her mother was diagnosed with multiple myeloma. At that age, the answer for Alex was that she needed to find a cure herself.

**Honorary Race Chair:**
Dr. Sagar Lonial, Winship Cancer Institute at Emory University

**Attendees:** ........................................ 496
**Funds Raised:** ........................................ $68,528
**Top Team:**
Sebia Stepping Up ........................................ $7,800
**Top Individual:**
Lou DePeters ........................................ $2,175

**Spirit of Hope Honoree:**
Justin Schaflander

Justin’s love for his mom has not gone unnoticed. As the Market President of iHeart Media in Atlanta, he plans to leverage his role with the company to make a big impact when it comes to generating awareness and raising funds for the MMRF. iHeart Media is the leading media company in America, delivering music, news, talk, sports, and other content to over 240 million listeners. They currently have the largest reach of any radio and television outlet in America. “We reach millions of people every day who can potentially help our cause,” explained Justin.

After humbly accepting the 2015 Spirit of Hope Award, we asked Justin, being new to the MMRF, what it meant to him to receive this prestigious award, and he said, “Receiving this award, is right up there with the most special moments in my life. I couldn’t be more proud of my family, especially my wife Wendy for supporting me in these tough times for our family and helping me with my efforts to make a difference in the lives of all the families who are impacted by multiple myeloma.”

**Honorary Race Co-chairs:**
Kathy Giusti and Walter M. Capone

**Attendees:** ........................................ 1,777
**Funds Raised:** ........................................ $355,963
**Top Team:**
Team Better Days ........................................ $98,113
**Top Individual:**
Gary Heinze ........................................ $10,385

**Spirit of Hope Honoree:**
Alex Burke

Alex Burke has been an inspirational young leader in this fight against multiple myeloma. In 2008, Team Darien was formed which included Alex’s family, friends and their Darien community. Over the past three years, Team Darien T-shirts had the slogan “Walk, Jog, Run, Sprint, Cure.” With this slogan, they encourage everyone to attend and participate in the race whether they are competing or walking. When Alex was 11, her mother was diagnosed with multiple myeloma. At that age, the answer for Alex was that she needed to find a cure herself.

**Tri-State (CT, NJ, NY)**
Kathy Giusti Appointed to President Obama’s Precision Medicine Initiative Working Group
The White House announced the establishment of the Personalized Medicine Initiative (PMI) working group to further its mission to improve care and speed the development of treatments through a new model of patient-powered research.

Forbes publishes an op-ed by Kathy Giusti
In May, MMRF Founder and Executive Chairman Kathy Giusti authored an op-ed for Forbes. It involves a topic that we are absolutely passionate about — the critical need for data sharing and integration to accelerate precision medicine and cures, not only for multiple myeloma but also for many cancers and other diseases.

MMRF presents awards at the 2014 ASH Annual Meeting
Each year, the MMRF recognizes exceptional work from its industry and academia partners. This year the Tisch Cancer Institute at the Mount Sinai Health System received the MMRF Innovator Award; Winship Cancer Institute at Emory University and the University of Chicago received the MMRF Accelerator Award; and Takeda Oncology received the MMRF Collaborator Award.

Kathy Giusti delivers keynote address at MassBio Annual Meeting
At the 2015 MassBio Annual Meeting in Cambridge in March, Kathy Giusti focused on how collaborative research systems can inject speed and efficiency into the drug discovery and development process in order to get treatments to patients faster. "It is an honor to share with MassBio our innovative model and hope that it accelerates progress in other cancers and diseases," she said.

MMRF and GNS Healthcare announce precision medicine collaboration
In January, the MMRF and GNS announced a collaboration to speed the discovery of innovative treatments for multiple myeloma through precision medicine. The effort will combine genomic and clinical data from the MMRF CoMMpass Study™ with GNS machine learning platforms and rapid computer simulations to provide a broader set of individualized treatment protocols.

To read more, visit themmrf.org/stories
MULTIPLE MYELOMA Patient Summit

You’re invited for a free day of learning and support.

August 22, 2015
Boston, MA
Program Chair
Paul Richardson, M.D.
at the Dana-Farber Cancer Institute

September 12, 2015
Chicago, IL
Program Chairs
Andrzej Jakubowiak, M.D., Ph.D.
and Todd Zimmerman, M.D.
at the University of Chicago

October 10, 2015
Seattle, WA
Program Chair
William I. Bensinger, M.D.
at the University of Washington School of Medicine

Visit themmrf.org/patient to register
or to watch Patient Summits from earlier this year in New York and Atlanta.
Calendar of Events

MMRF Signature Events

October 24, 2015  MMRF Annual Fall Gala  Greenwich, CT
Spring 2016  MMRF Laugh for Life: New York  New York, NY
Spring 2016  MMRF Chicago Awards Dinner  Chicago, IL

MMRF Endurance Events

September 27, 2015  BMW Berlin Marathon  Register Online
October 2-3, 2015  Ragnar Relay D.C.  Register Online
October 11, 2015  Bank of America Chicago Marathon  Register Online
October 18, 2015  IRONMAN® 70.3 Arizona  Register Online
November 1, 2015  TCS New York City Marathon  Register Online
November 7, 2015  Spartan Fenway Park Sprint (Stadium)  Register Online
April 2016  Virgin London Marathon  Register Online
July 2016  IRONMAN® Lake Placid  Register Online

MMRF 5K Walks/Runs

September 13, 2015  Chicago  Register Online
September 27, 2015  Twin Cities  Register Online
November 14, 2015  Philadelphia  Register Online
November 15, 2015  Washington D.C.  Register Online
November 21, 2015  New York City  Register Online

MMRF Patient Summits

August 22, 2015  Chair: Dr. Paul Richardson  Dana-Farber Cancer Institute  Boston, MA
September 12, 2015  Chairs: Drs. Andrzej Jakubowiak & Todd Zimmerman, University of Chicago  Chicago, IL
October 10, 2015  Chair: Dr. William Bensinger  Seattle Cancer Care Alliance  Seattle, WA

The information herein is not intended to replace the services of trained health professionals (or to be a substitute for medical advice). You are advised to consult with your healthcare professional with regard to matters relating to your health and, in particular, regarding matters which may require diagnosis or medical attention.

Copyright ©2015 Multiple Myeloma Research Foundation
THE 100,000 PEOPLE WHO SUPPORT THE MMRF CAMPAIGN. DONATE NOW.

We are halfway to our goal of raising $100 million to fuel data and diagnostics, create world class networks of expertise, and build collaborative platforms and analytic tools to drive new treatments to the clinic.

Now is a transformative point in time. Be a part of it.

WE ARE CURING CANCER NOW

PLEASE SUPPORT THE MMRF CAMPAIGN. DONATE AT THEMMRF.ORG/DONATE